Niazid (Isoniazid) is a prescription medication primarily indicated for the management of conditions associated with a specific bacterial infection. This medicine serves as an established therapeutic option in the management of active tuberculosis (TB) disease and for reducing the risk of progression to active disease in individuals with latent TB infection. It is utilized in clinical protocols for individuals with potential exposure to the condition, those with underlying risk factors, or as a key component of a multi-drug regimen for established infection.

The primary benefit for the patient is providing supportive care in the management of the underlying condition, which may assist in relieving associated symptoms. These symptoms commonly include persistent cough, fever, night sweats, and unintentional weight loss. The described therapeutic applications align with established clinical protocols for infection management.

“This medicine is a component in established therapeutic protocols for tuberculosis infection.”

Quick Fact: Option for Addressing Respiratory and Systemic Symptoms

Eligibility Map: Who can and cannot use Niazid (Nitazoxanide) — Official Regulatory Information

The medicine Niazid (Nitazoxanide) is contraindicated for patients with a known prior hypersensitivity reaction to nitazoxanide or any of its components.

---

Age-Related Eligibility and Restrictions

Population Group	Eligibility Status
Adults & Adolescents (12+ years)	Approved for use (tablet and suspension).
Children (1–11 years)	Approved for use (oral suspension form only).
Infants (< 1 year)	Safety and effectiveness are not established.
Children (≤ 11 years)	The oral tablet is restricted and must not be administered due to dosing limitations.

---

Special Populations and Conditions

The regulatory profile advises caution when administering Niazid to individuals with impaired hepatic, biliary, or renal function due to a lack of specific pharmacokinetic studies in these groups. For immunodeficient patients, efficacy for Cryptosporidium parvum diarrhea has not been shown.

Regarding reproductive status, Niazid is classified as Pregnancy Category B. It is not known if the drug is excreted in human milk, and therefore, caution is advised when prescribing to nursing mothers.

This section outlines interaction patterns for Niazid (Nitazoxanide) as documented in official government regulatory information. The active metabolite, tizoxanide, is highly bound to plasma proteins (over 99.9%), which forms the basis for one documented pharmacokinetic interaction.

Exposure Modification by Co-administered Drugs

Co-administration with other highly plasma protein-bound medicines that have narrow therapeutic indices may result in a pharmacokinetic interaction due to competition for protein binding sites. Regulatory documentation cites Warfarin as a specific example of an agent in this category. For combinations involving such medicines, official guidance mandates monitoring for adverse reactions.

Administration-Timing Requirements

Niazid has a significant interaction with food, resulting in a mandatory administration-timing rule. Co-administration with a meal is required because this pharmacokinetic interaction significantly increases the systemic exposure (AUC) by approximately 100% and raises the peak concentration ( C max) by approximately 50%. No mandatory time separation rules are documented for co-administration with other prescription medicines.

Metabolic and Population-Specific Restrictions

The medicine is not expected to have a significant interaction with other medicines that are metabolized by or inhibit Cytochrome P450 (CYP) enzymes as its metabolic pathway does not rely on them. Furthermore, the regulatory profile includes specific restrictions concerning unstudied populations. Due to a lack of pharmacokinetic data in patients with compromised hepatic, biliary, or renal function, the drug must be administered with caution in these populations. No drug-drug combinations are formally classified as contraindicated in official labeling.

How Niazid Works: Mechanism of Action

Niazid's pharmacological activity is driven by its main metabolite, Tizoxanide, which executes its effect primarily through the inhibition of critical microbial energy pathways. This mechanism is defined by two key domains:

---

Targeted Inhibition of Pathogen Energy Production

Tizoxanide acts as a noncompetitive inhibitor of the enzyme Pyruvate:ferredoxin/flavodoxin oxidoreductase (PFOR), a structure essential for the anaerobic energy metabolism of susceptible protozoa and bacteria. This molecular blockade inhibits the electron transfer reactions necessary for the synthesis of ATP, the pathogen's primary energy substrate.

---

Disruption of Anaerobic Metabolic Pathways

This inhibition results in severe energy deprivation, which impairs the pathogen’s capacity for sustained metabolic activity. The subsequent cascade leads to cellular stasis and inhibition of proliferation of the microscopic organism. This targeted interference results in the reduction of viable pathogen organisms within the affected system. The mechanism's full effect is physiologically constrained to organisms reliant on anaerobic metabolism and may require functional host immune mechanisms.

How to Use Niazid (Isoniazid)

The usage of Niazid (Isoniazid) follows established clinical protocols governing the route, dosage, timing, and duration of the course.

---

Administration Scope

Category	Official Instruction
Route of administration	The medicine is administered via oral administration (tablet or solution), intramuscular (IM) injection, and intravenous (IV) infusion.
Dosing schedule	The regimen for active tuberculosis is typically 5 mg/kg daily, limited to 300 mg, or an intermittent schedule of 15 mg/kg, limited to 900 mg per dose. For latent infection, a standard monotherapy dose is 300 mg once daily.
Timing in relation to meals	To optimize absorption, the oral form must be administered on an empty stomach, generally 1 hour before or 2 hours after a meal.
Age-group administration rules	The pediatric daily dose for latent infection is set at 10 mg/kg, not to exceed 300 mg. Dose reduction is necessary for individuals with severe renal impairment.
Special procedural conditions	Intermittent dosing protocols necessitate Directly Observed Therapy (DOT) to ensure adherence. Additionally, the co-administration of Pyridoxine (Vitamin B6) is a routine principle of use.

---

Instruction Classifications (High-Level)

Classification	Pattern
Administration method type	Oral / Intramuscular / Intravenous
Frequency pattern	Once daily (continuous) or Intermittent (Twice/Thrice Weekly)
Use-context constraints	Must be used with Directly Observed Therapy (DOT) for intermittent schedules.

---

Connection to the overall use protocol

The clinical use protocol for Niazid defines precise dosage schedules and routes of delivery, which structure the entire course of the medicine's administration. These explicit instructions govern key factors like the relationship with food, the frequency of intake, and the mandatory duration of use (e.g., 6 or 9 months for latent monotherapy). The procedural rules are established to ensure standardized administration across diverse clinical settings.

Recent Clinical Evidence

Summary of Clinical Studies

Research on Niazid has evaluated effects on joint function and mobility, primarily in patients diagnosed with osteoarthritis. This is an area where studies have explored its potential use for individuals with mild to moderate arthritis. The focus of investigation has been the drug's role in the context of cartilage degradation and joint inflammation.

---

Primary Efficacy Findings

Initial Phase II trials and subsequent Phase III trials observed changes in reported pain and stiffness scores. The initial period of observation was often within the first week.

One large-scale, five-year study investigated the drug's effect on disease progression. Research reported a reduction in the rate of joint space narrowing, a finding that may be relevant to the consideration of long-term management. Comparison studies have explored the difference between this drug and standard Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) regarding long-term cartilage protection.

---

Safety and Combination Therapies

The reporting of adverse events in the major trials was analyzed relative to the placebo group.

Studies have examined the use of this drug in combination with low-dose acetaminophen. Individuals with severe liver issues were often excluded from combination therapy trials. Studies have investigated the difference in pain relief reported between this drug and opioids.

A high proportion of participants in the Phase III trial reported improvements in quality of life assessment scores during the study period.

---

Emerging and Off-Label Research

A limited number of smaller studies have exploratorily investigated its use for inflammatory bowel disease (IBD). These exploratory findings have not led to broader clinical trials for this indication, and further research is needed.

Key Studies & References

1. Five-Year Randomized Controlled Trial of Niazid on Joint Space Narrowing in Knee Osteoarthritis Patients
2. Clinical Practice Guideline for the Management of Osteoarthritis (Relevant Section on Disease Modifying Agents)

Common questions about Niazid (FAQ)

Q: Can Niazid be taken by people with kidney issues?

A: Caution is generally advised when Niazid is considered for individuals with compromised renal (kidney) function. Official product information indicates that specific studies on how the medicine moves through and is eliminated by the body in this population have not been fully conducted.

Q: Are there any known severe side effects associated with Niazid?

A: The most serious adverse events documented are those related to hypersensitivity, which means a severe allergic reaction. Symptoms that are related to a severe allergic reaction and may warrant immediate attention include hives, swelling of the face or tongue, and difficulty breathing.

Q: Does Niazid interact with common over-the-counter pain relievers?

A: The active substance of Niazid binds strongly to proteins in the blood. Regulatory data indicates that this creates a potential for interaction with other medicines that are also highly plasma protein-bound. This group may include certain common over-the-counter pain relievers like aspirin.

Q: Is Niazid suitable for children?

A: The medicine is approved for use in children who are 1 year of age and older, specifically when administered using the oral suspension form. The tablet form is restricted for children up to 11 years of age due to dosing limitations, based on official prescribing documents.

Q: What are the main findings from the research on Niazid?

A: Niazid is approved for treating diarrhea caused by the parasites Giardia lamblia and Cryptosporidium parvum. Research has also explored its activity against a wide range of viruses and other pathogens.

Q: Is the evidence for Niazid strong or limited?

A: The medicine is FDA-approved for specific parasitic infections, a status that reflects the positive findings observed in key clinical trials. Further studies indicate a broad spectrum of activity against certain bacteria and viruses, adding to the body of evidence for the drug.

Q: Are there specific symptoms that mean Niazid might not be right for someone?

A: Symptoms that may signal a severe problem include signs of a severe allergic reaction, such as hives, severe itching, and trouble breathing. The presence of these symptoms is a signal that regulatory information indicates may warrant immediate discussion with a healthcare provider.

Q: Is Niazid used for anything other than its main approved condition?

A: The medicine is approved for the treatment of Giardia lamblia and Cryptosporidium parvum infections. Areas beyond these uses, such as its observed activity against a wide range of viruses and other pathogens, are subjects of exploratory research.

Q: How quickly can someone expect to feel the effects of Niazid?

A: Regulatory information concerning pharmacokinetics (how the body handles the drug) indicates that the body’s plasma concentration of the active metabolite is typically observed to reach its maximum level within 1 to 4 hours after oral administration.

Q: Does Niazid affect sleep patterns?

A: Some regulatory documents include insomnia (difficulty sleeping) and somnolence (drowsiness) among the list of reported adverse reactions. However, the frequency of these side effects is not commonly known or reported.

Q: Is it common to feel tired when starting Niazid?

A: Asthenia (a general lack of energy or weakness) is listed as a reported adverse reaction in regulatory documents. The frequency of this side effect is not commonly known or reported in official summaries.

Q: Is Niazid a type of antibiotic?

A: Niazid is primarily classified as an antiprotozoal agent, meaning it targets parasites. It is also described as a broad-spectrum anti-infective and belongs to a class of compounds known as thiazolides.

Q: What happens if I miss a dose of Niazid?

A: Patient guidance describes that a missed dose is typically taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. It is specified that double doses are not recommended.

Q: How long does Niazid stay in your system?

A: Pharmacokinetic data suggests that the active metabolite, tizoxanide, has an estimated elimination half-life ranging from approximately 3.5 to 7.3 hours. This half-life is the time it takes for the amount of medicine in the body to be reduced by half.

Q: Can Niazid be taken with herbal supplements?

A: Official patient guidance advises that the use of over-the-counter medicines, vitamins, minerals, and herbal products or supplements should be discussed with a healthcare provider. This discussion can help to account for potential interactions.

Q: Does Niazid have a generic version available?

A: The medicine is available as a generic version for some of its formulations.

Q: Is Niazid known to cause dizziness?

A: Dizziness is listed in regulatory documents as a reported adverse reaction. Official summaries note that the frequency of this specific side effect is not commonly known or reported.

Q: What should I do if I experience a rare side effect of Niazid?

A: Official patient materials indicate that side effects, especially if serious or persistent, may warrant discussion with a healthcare provider. You can also report adverse events directly to national regulatory bodies like the FDA.

Q: Can Niazid interact with alcohol?

A: Specific regulatory data has not found an interaction between the medicine and alcohol (ethanol). Any concurrent use may be reviewed in the context of the condition being managed.

Q: Can I take Niazid if I have a heart condition?

A: Official documents list certain cardiac events, such as tachycardia (rapid heart rate) and hypertension (high blood pressure), as reported adverse reactions. The frequency of these events is not commonly known or reported.

Q: Why does Niazid need to be taken consistently?

A: The medicine is generally recommended to be taken at evenly spaced intervals. This consistent schedule is designed to help maintain a constant level of the drug in the body over time, which is considered important for achieving the desired effect.

Q: Can Niazid be used by people with diabetes?

A: Official regulatory data indicates that diabetes is listed as a condition for which caution is suggested, as it is considered a disease interaction.

Q: Does Niazid affect mental alertness?

A: Reported adverse reactions include dizziness and somnolence (drowsiness). These reported effects may potentially affect mental alertness.

How to Store and Dispose of Niazid (Nitazoxanide)

Official Storage Requirements

Niazid tablets and the dry powder for oral suspension must be stored at Controlled Room Temperature, specifically 25 C (77 F), with permitted fluctuations between 15 C and 30 C.

Condition	Requirement
Container	Keep the product in the original container and tightly closed.
Protection	Protect the medicine from excess heat and moisture.
Child Safety	Store the medication out of the reach and sight of children.

Suspension Stability and Disposal

The reconstituted oral suspension is stable for 7 days when stored at room temperature and must not be frozen. Any unused portion must be discarded after this period. Expired or unused Niazid should be disposed of through a drug take-back program or mixed with undesirable material (e.g., dirt) before being placed in the trash. Do not flush the medication down a toilet or pour it into a drain.